|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||17.40 - 17.91|
|52 Week Range||7.59 - 42.62|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Anyone researching DBV Technologies S.A. (EPA:DBV) might want to consider the historical volatility of the share...
Aimmune Therapeutics Inc (NASDAQ: AIMT )'s peanut allergy product candidate Palforzia to treat peanut allergy in children and adolescents has received the backing of an FDA panel that reviewed the NDA. ...
DBV said late Wednesday it has submitted its Biologic License Application, or BLA, for Viaskin Peanut, which is being evaluated for treating peanut-allergic children ages 4-11. Viaskin Peanut, an epicutaneous immunotherapy, is DBV's proprietary investigational platform designed to leverage the skin to activate the immune system and induce desensitization to allergens. In December 2018, the company voluntarily withdrew its prior BLA submission after the FDA communicated the need for additional data on manufacturing procedures and controls.
DBV Technologies S.A. (EPA:DBV) shareholders should be happy to see the share price up 18% in the last month. But that...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! DBV Technologies S.A. (EPA:DBV) is a stock Read More...
DBV said Wednesday after the close it has voluntarily withdrawn its Biologic License Application, or BLA, for Viaskin Peanut in children 4-11. The decision to withdraw the application was made at the behest of the FDA, which communicated its decision orally and in writing Dec. 18. Reacting to the development, Bank of America Merrill Lynch analyst Tazeen Ahmad downgraded DBV from Buy to Underperform and reduced the price target from $30 to $8.
In 2002 Pierre-Henri Benhamou was appointed CEO of DBV Technologies SA (EPA:DBV). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...